RxDoctor Payments Data

Megan Comer, PA

Physician Assistant · Charlotte, NCNPI 1689092587

Payments from drug & device makers

$1,625in general payments, 2019–2025

Across 79 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$298
  • Supernus Pharmaceuticals, Inc.$170
  • Tris Pharma Inc$154
  • AbbVie$139
  • Neurocrine Biosciences, Inc.$130
  • Teva Pharmaceuticals USA, Inc.$128
  • plus $607 from 11 others

What the payments were for

  • Food & beverage$1,61699%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,625 in reported general payments places this provider in the 75th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$13,206
Medicare patients
20
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl11$26,002
RexultiBrexpiprazole13$22,193
Lurasidone Hcl26$21,599
TrintellixVortioxetine Hydrobromide13$11,879
Lisdexamfetamine Dimesylate16$2,084
Zolpidem Tartrate ErZolpidem Tartrate12$1,258
Ramelteon24$1,044
Duloxetine Hcl33$993
Lamotrigine85$890
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine33$769
Clonazepam64$674
Quetiapine Fumarate43$582
Olanzapine34$548
Buspirone Hcl46$466
Bupropion XlBupropion Hcl32$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$139$26,00211 claims
Otsuka America Pharmaceutical, Inc.Rexulti$40$22,19313 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$298$11,87913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →